## Highlights of This Issue 5145

### SPECIAL FEATURES

**CCR Translations**

5147  Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!  
Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein  
See related article, p. 5290

5147  Human T-cell Lymphotrophic Virus Type I-Associated Adult T-cell Leukemia-Lymphoma: New Directions in Clinical Research  
Kunihiro Tsukasaki and Kensei Tobinai

5226  Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?  
Emmanuel Bachy and Gilles Salles

**CCR New Strategies**

5150  New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances  
Joyce Liu and Ursula A. Matulonis

**Molecular Pathways**

5157  Molecular Pathways: Myeloid Complicity in Cancer  
Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

**CCR Focus**

5172  The Lymphoma Medicine Cabinet  
Susan E. Bates

5173  Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context  
Owen A. O’Connor and Kensei Tobinai

5182  Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype  
Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

5194  New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?  
Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klapper on behalf of the European Mantle Cell Lymphoma Network

5207  Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas  
Emanuele Zucca, Francesco Bertoni, Barbara Vannata, and Franco Cavalli

5217  Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice  
Owen A. O’Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D’Amore, Dejan Radeski, and Susan E. Bates

**CANCER THERAPY: CLINICAL**

5255  A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies  
Timothy S. Pardee, King Lee, John Ludy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

5265  Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer  
Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritschler, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans

**PERSONALIZED MEDICINE AND IMAGING**

5265  Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer  
Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritschler, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans
Table of Contents

5272 Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Trine Tramm, Hayat Mohammed, Simen Myhre, Marianne Kyndt, Jan Alsner, Anne-Lise Borresen-Dale, Therese Sørlie, Arnoldo Frigessi, and Jens Overgaard

5281 Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve A. Lowery, Leonard B. Saltz, Joseph F. Crotty, Kristen Gary, Brandon Cooper, Rená Lapidus, Mariola Sadowska, and Eileen M. O’Reilly

CANCER THERAPY: PRECLINICAL

5290 Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak

See related commentary, p. 5147

5311 Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Stefán Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakhit, Aidan Noon, Wei Chen, and James WF Catto

5322Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

BIOLOGY OF HUMAN TUMORS

5302 Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni

CORRECTION

5339Correction: Targeting miR21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.